Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
About this item
Full title
Author / Creator
Loomba, Rohit , Hartman, Mark L. , Lawitz, Eric J. , Vuppalanchi, Raj , Boursier, Jérôme , Bugianesi, Elisabetta , Yoneda, Masato , Behling, Cynthia , Cummings, Oscar W. , Tang, Yuanyuan , Brouwers, Bram , Robins, Deborah A. , Nikooie, Amir , Bunck, Mathijs C. , Haupt, Axel , Sanyal, Arun J. and SYNERGY-NASH Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than placebo with respect to resolution of MASH without worsening of fibrosis.
Alternative Titles
Full title
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_05003023v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_05003023v1
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2401943
